Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

Positive phase III results reported for Ergoset monotherapy

Dec. 24, 1996

Androsorb cleared for clinical trials

Dec. 23, 1996

ImClone and Immunex crosslicense flt3/flk-2 technology

Dec. 23, 1996

Third approval for Parke-Davis HMG-CoA reductase inhibitor

Dec. 23, 1996

Fujisawa synthesizes novel bone resorption inhibitors

Dec. 20, 1996

Grelan, Fournier collaborate on ACAT inhibitors

Dec. 20, 1996

Shaman and Ono expand diabetes collaboration

Dec. 18, 1996

Pamidronate effective against skeletal complications in breast cancer patients

Dec. 18, 1996

Troglitazone hypotensive, hypoglycemic activities established in preclinical model

Dec. 18, 1996

Licenses offered for the use of IL-7 in increasing hematopoietic stem cells

Dec. 17, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.